We reflect on the past 12 months from the patient perspective – it has been a phenomenal year of successes, stories and surprises.
by David Laws
Customer Centricity, Communities of Practice, Big Data, Patient Centricity (probably), The Digital Organization and many more business model innovations have failed to take serious hold in pharma over the years.
With patient centricity firmly on the agenda, what is true patient centricity and how can we translate the intent to align more with action? I interviewed executives at Novo Nordisk and Sanofi to highlight the three key things to consider when seeking to be patient centric.
by Marc Yates
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.
There is an epidemic of sticking roughly to the previous year's plan and budget. This may be useful if that approach is getting you to be the top brand, but if your results are not radically improving you need to examine both your strategy and budget allocation carefully.
by Paul Simms
Rice Powell, Chairman of the Board and CEO for Fresenius Medical Care, speaks to Paul Simms, eyeforpharma Chairman. Fresenius Medical Care is a company well-known for being the first to successfully pioneer a vertically-intergrated, service-oriented model within healthcare.
by Jeff Elton
As we enter into the "Value Era", innovating and delivering value is about understanding critical connections, gaps, and potential solutions or alternatives to each. Jeff Elton discusses the exciting emergence of a truly global health services solutions market.
Although the exchanges have the potential to expand the market for some therapeutic areas, the way in which they are designed will likely have an impact on consumer purchasing behavior. Manufacturers need to understand how consumers are responding and what these changes mean for their business.
Female millennials matter because they are more highly educated than previous generations (according to research) and are set to represent 25% of the global workforce by 2020. However, meeting their employer expectations is a challenge that requires deep insight into their behaviors and motivations.
Biosimilars face a dual challenge of competing with the original product’s clinical and marketing profile, i.e. are they both biosimilar and market similar. In this competitive environment, whatever approach biosimilar manufacturers select must demonstrate how their product adds value.
Following her keynote presentation at eyeforpharma Barcelona 2014, Jane Griffiths, Janssen Company Group Chairman, EMEA, was interviewed by Paul Simms, eyeforpharma Chairman, and discusses how the pharmaceutical industry needs to build trust through collaboration.